Azithromycin structure

Azithromycin – CAS 83905-01-5

€100 – €200

Azithromycin is provided by Santiago Lab. It is one of the 5 compounds recommended by WHO for the investigation of the treatment of COVID-19. You can order Azithromycin individually or as a set of 5 antivirotics recommended by WHO.

Purity (LC-MS)

98 %  |  Certificate of Analysis

Package contents 

Azithromycin hydrate

This compound is for research use only. We do not sell to patients.
SizeAvailabilityPriceQuantity
100 mg

In stock

 €100
1 g

In stock

 €200

Characterisation

CAS: 83905-01-5

IUPAC Name: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one

Other names: Azadose; Goxal; Sumamed; Ultreon; CP 62993; Zithromax; Azitrocin; Azythromycin; Azithromycin

Molecular weight: 749.00 g/mol

Molecular formula: C38H72N2O12

Description

Azithromycin is an antibiotic used for the treatment of a number of bacterial infections (middle ear infections, strep throat, pneumonia, traveller’s diarrhoea) or number of sexually transmitted infections (chlamydia and gonorrhoea infections). Along with other medications, it may also be used for malaria. Recently the combination of azithromycin with antiviral drug hydroxychloroquine was found to be more efficient in the treatment of COVID-19.

Azithromycin was discovered in 1980 by Pliva and approved for medical use in 1988. It is one of the Essential Medicines in the World Health Organization’s List, the safest and most effective medicines needed in a health system. Azithromycin belongs to family of azalides, a type of macrolide antibiotic. It works by decreasing the production of protein, thereby stopping bacterial growth.

Chemicals are distributed worldwide

Buy Azithromycin now, get your order in 48 hours
  • Shipping through DHL in 48 hours 
  • All compounds are safely and rigorously packed

Payment

  • We are sending the invoice the same day as the shipment
  • We are able to modify the invoice for the academic institution, so the order can be paid from grants
References

1. Lover, A. A., Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020). medRxiv 2020.
2. Giwa, A.; Desai, A., Novel coronavirus COVID-19: an overview for emergency clinicians. Emerg Med Pract 2020, 22 (2 Suppl 2), 1-21.
3. Gautret, P.; Lagier, J.-C.; Parola, P.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V. E.; Dupont, H. T., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents 2020, 105949.
4. Tita, A. T.; Szychowski, J. M.; Boggess, K.; Saade, G.; Longo, S.; Clark, E.; Esplin, S.; Cleary, K.; Wapner, R.; Letson, K., Adjunctive azithromycin prophylaxis for cesarean delivery. New England Journal of Medicine 2016, 375, 1231-1241.
5. Stokholm, J.; Chawes, B. L.; Vissing, N. H.; Bjarnadóttir, E.; Pedersen, T. M.; Vinding, R. K.; Schoos, A.-M. M.; Wolsk, H. M.; Thorsteinsdóttir, S.; Hallas, H. W., Azithromycin for episodes with asthma-like symptoms in young children aged 1–3 years: a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine 2016, 4 (1), 19-26.
6. Retallack, H.; Di Lullo, E.; Arias, C.; Knopp, K. A.; Laurie, M. T.; Sandoval-Espinosa, C.; Leon, W. R. M.; Krencik, R.; Ullian, E. M.; Spatazza, J., Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proceedings of the National Academy of Sciences 2016, 113 (50), 14408-14413.
7. Galante, O.; Avni, Y. S.; Fuchs, L.; Ferster, O. A.; Almog, Y., Coronavirus NL63-induced adult respiratory distress syndrome. American journal of respiratory and critical care medicine 2016, 193 (1), 100-101.
8. Albert, R. K.; Connett, J.; Bailey, W. C.; Casaburi, R.; Cooper Jr, J. A. D.; Criner, G. J.; Curtis, J. L.; Dransfield, M. T.; Han, M. K.; Lazarus, S. C., Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine 2011, 365 (8), 689-698.
9. Alvarez-Elcoro, S.; Enzler, M. J. In The macrolides: erythromycin, clarithromycin, and azithromycin, Mayo Clinic Proceedings, Elsevier: 1999; pp 613-634.
10. Dunn, C. J.; Barradell, L. B., Azithromycin. Drugs 1996, 51 (3), 483-505.
11. Peters, D. H.; Friedel, H. A.; McTavish, D., Azithromycin. Drugs 1992, 44 (5), 750-799.
12. Hopkins, S., Clinical toleration and safety of azithromycin. The American journal of medicine 1991, 91 (3), S40-S45.
13. Foulds, G.; Shepard, R.; Johnson, R., The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 1990, 25 (suppl_A), 73-82.

Related products: